Cancer
Our anti-cancer services facilitates the development of novel agents using our cell-based anti-cancer screening program. This platform charcterizes the mechanism of action of new products using cell-based, biochemical, immunologic, and genomic and proteomic based assays. The ImQuest BioSciences' staff has decades of experience with the efficient and cost-effective development of chemotherapeutic agents for the treatment of cancer. Request a quote for Oncology Services.
ImQuest BioSciences performs the following anti-cancer product development services:
Anti-Proliferative Screening Assays
- Cell-based anti-cancer activity evaluations using the ImQuest BioSciences' OncoSENS platform, which consists of 120 cancer cell lines for the screening of small molecules and biologics
- Clonogenic assays to complement the anti-proliferative assays, differentiating between cytotoxic and cytostatic modes of action
- Biochemical and molecular target-based screening assays
Mechanism of Action Evaluations in Cell-based, Immunologic, and Biochemical Assays
- Direct evaluation of specific inhibitory pathways: cell cycle arrest, apoptosis, kinases, growth factors and signal transduction
- Resistance selection an characterization of resistant clones
- Inhibitory pathway validation using binding studies, qPCR, IHC, siRNA, microarrays and flow cytometry
- Immunophenotyping and cytokine analysis using state-of-the art multi-color flow cytometer, ELISA and cytokine profiling
Evaluation of Combination Anti-Cancer Therapeutic Approaches
- Statistical analysis of drug combination effects using highly sensitive checkerboard evaluations
Rodent Xenograft and Other In Vivo Models of Compound Efficacy
Evaluation of Off-Target Effects and Safety Profiling
- Screening for potential toxicity of lead therapeutics in primary cell lines
- Screening for immune-toxic effects
- Identification of biomarkers in the preclinical or clinical setting
- Support for pharmacokinetic/pharmacodynamic studies, and immunogenicity
